Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Neoplasms 6Venous Thromboembolism 3Venous Thrombosis 2Thrombosis 2Thromboembolism 2Prostatic Neoplasms 2Unspecified Adult Solid Tumor, Protocol Specific 1Sarcoma, Alveolar Soft Part 1Pulmonary Embolism 1Prostate Cancer Patients 1Pharmacokinetics of MDV3100 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma 1Hematologic Neoplasms 1Embolism and Thrombosis 1Embolism 1Cytochrome P450 Interaction 1Advanced Solid Tumor 1ALK-positive Advanced Tumors 1

Interventions

pembrolizumab 156Gemcitabine 139Capecitabine 121Paclitaxel 119Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 93Cisplatin 90Irinotecan 88Carboplatin 85Radiosurgery 83Cyclophosphamide 71Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × Warfarin × Clear all
NCT02688088 2022-10-18

A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body

Eli Lilly and Company

Phase 1 Completed
48 enrolled 30 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡